Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Barclays Global Healthcare Conference 2021
31 slides from Angiodynamics's conference presentation, Mar 9, 2021
Slide 1: Barclays Global Healthcare Conference
03 | 09 | 2021 ANGIODYNAMICS Barclays Global Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litiga
Slide 2: Strategic Transformation
PURSUIT OF LARGER MARKETSActive portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment is focused in areas that offer best opportunities for success PORTFOLIO TRAN
Slide 3: Strategic Transformation
ANGIODYNAMICS Strategic Transformation i>) angiodynamics PURSUIT OF LARGER MARKETS Active portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENT Resource deploymentis focused in area
Slide 4: Focused Transformation: U.S. Total Addressable Markets
4 FOCUSED TRANSFORMATIONU.S. Total Addressable Markets Our strategic initiative to become a growth company begins 2018 Launch of the Auryon System gives us access to the peripheral atherectomy market New Thrombectomy & NanoKnife System portfolio additions & indications increase market access $1.3B 0
Slide 5: Invest for Growth
INVEST FOR GROWTH Peripheral Atherectomy ON Thrombus Management AngioVac Uni-Fuse Irreversible Electroporation i>) angiodynamics Vascular Access Catheters and Accessories Diagnostic Catheters, Guidewires and Kits Endovenous Laser Treatment Microwave & Radiofrequency Tumor Ablation Lung Biopsy Safety
Slide 6: Focused Investment
6 FOCUSED INVESTMENT Healthy Blood Flow to the Heart Expanded Treatment Options in Oncology Leveraging 3 main drivers to carve out our space in large, growing markets through innovative, disruptive technologies that treat patients with cancer, promote healthy blood flow and deliver critical therapie
Slide 7: Peripheral Atherectomy
PERIPHERAL ATHERECTOMY 03 | 09 | 2021 7 2.35 mmAspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mmAspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mmIndicated for Peripheral Atherectomy Why wavelength mattersE
Slide 8: Peripheral Atherectomy: US Addressable Markets & Competitive Landscape
PERIPHERAL ATHERECTOMYUS Addressable Markets & Competitive Landscape MECHANICAL LASER $555M 23%1 1. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millennium Research Group, Inc. 77%1 2020 Total Addressable Market (TAM) 9 Company Product Thrombus Plaque Fibrotic I
Slide 9: Peripheral Atherectomy: Continuing our momentum of growth
10 PERIPHERAL ATHERECTOMYContinuing our momentum of growth PRODUCT DEVELOPMENT Product development pipelinePortfolio and product indication expansionContinuous voice of customer CLINICAL COMPENDIUMExpand awareness by creating a strong podium and clinical publication presence Clinically differentiate
Slide 10: Thrombus Management
THROMBUS MANAGEMENT 03 | 09 | 2021 11
Slide 11: Deep Vein Thrombosis and Pulmonary Embolism
12 Deep Vein ThrombosisDVT + Pulmonary EmbolismPE = Venous ThromboembolismVTE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs, blocking some or all of the blood supply DVT and PE are collectively referred to as VTE 208
Slide 12: DVT & PE Treatment Options
13 DVT & PE TREATMENT OPTIONSPercutaneous Thrombectomy CDT & US-CDTCatheter-Directed Thrombolysis (with or without the assistance of ultrasound) PCMTPharmacomechanical Thrombectomy AngioVacContinuous Aspiration Suction Thrombectomy MTMechanical Retrieval Thrombectomy MAMechanical Aspiration(Small &
Slide 13: Thrombus Management: Purpose Built Portfolio & Technology
THROMBUS MANAGEMENTPurpose Built Portfolio & Technology 14 Right Atrium AngioVac’s use is currently focused on the Right Atrium, which is a $77M addressable market. Pulmonary Embolism Deep Vein Thrombosis A multi-purpose mechanical aspiration device will allow us to compete in the broader DVT & PE a
Slide 14: The AngioVac Difference
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous systemUtilizing a self-expanding, nitinol reinforced funnel tipSimultaneously reinfusing the patient’s own filtered blood to limit procedural blood lo
Slide 15: Thrombus Management: Planned Portfolio Additions & Addressable Markets
THROMBUS MANAGEMENTPlanned Portfolio Additions & U.S. Addressable Markets Expansion 16 $1.3B $1.6B FY 2021 FY 2022 FY 2023 FY 2025 FY 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 $140M $700M $3.6B $1.5B 1 2 The planned portfolio additions are not guarantees of future performance
Slide 16: Irreversible Electroporation
IRREVERSIBLE ELECTROPORATION 03 | 09 | 2021 17
Slide 17: Irreversible Electroporation: Non-thermal energy destroys cells
18 Probe placement Placement of probes around a target area provides effective treatment coverage a-d Electrical pulses cause pores to form within the cellular membrane leading to non-thermal cell death a-d Electrical field Decellularization Non-thermal Revascularization The NanoKnife System’s uniqu
Slide 18: Provides the Innovation Doctors Need
19 Localized Treatment Strong safety profile Maintains potential for future treatments Provides options for patients PROVIDES THE INNOVATION DOCTORS NEEDExpands treatment options and helps preserve patient's quality of life Spares critical structures and nerves Treated tissue can revascularize Prese
Slide 19: DIRECT Study and Prostate IDE
20 DIRECT StudyThis study is evaluating the use of the NanoKnife System as a potential treatment for stage III pancreatic cancer. Prostate IDEThis safety study will evaluate the use of the NanoKnife System as a focal therapy option for prostate tissue. Liver Oral Cavity Pancreas Kidney Bladder Melan
Slide 20: DIRECT Study: Data for IRE Cancer Treatment
21 DIRECT STUDYData for IRE Cancer Treatment Randomized Controlled Protocol Controlled Registry Protocol One Study Two Protocols Highest level of evidence and real-world evidence Overall Survival as primary endpoint Both have prospective control arms
Slide 21: Focal Therapy in Prostate Cancer
22 Focal therapy bridges the gap between whole gland treatment and active surveillance in an attempt to maximize quality of life by avoiding the effects of whole gland radiation or surgery.However…adoption remains low (<5%) due to gaps within existing technology. 27% will undergo radiotherapy of whi
Slide 22: NanoKnife Platform: Expanding Indications
23 The Team Expanding Indications Pancreas pivotal study underway (DIRECT)Prostate safety study underwayFDA Pre-Sub meeting regarding prostate tissue indication complete InpatientICD-10 Code (2018)DRGs (2019)Organ Agnostic CPT Code (2020)OutpatientOutpatient (2021)ASC (2021) ExpandedReimbursement NA
Slide 23: Vascular Access
VASCULAR ACCESS 03 | 09 | 2021 24
Slide 24: Vascular Access: Safely delivering medication to patients
25 VASCULAR ACCESSSafely delivering medication to patients PORTFOLIO MARKET ACCESS PERFORMANCE PICCs Midlines Tip Location Ports Dialysis Point of Care Ultrasound Delivering on our product road map including development of an integrated navigation & tip location technology that enables the use of ou
Slide 25: First Half FY2021 Highlights
First Half FY2021 Highlights $ in Millions (except per share data) 1H FY2021 1H FY2020 YOY Change Revenue $143.0M $136.0M 5.1% Gross Margin 53.1% 58.6% (550 bps) Net Loss ($8,536) ($4,011) ($4,525) GAAP EPS ($0.22) ($0.11) ($0.11) Adjusted EPS $0.03 $0.14 ($0.11) Adjusted EBITDA $9.6 $13.7 $4.1 Fina
Slide 26: Strategic Transformation
PURSUIT OF LARGER MARKETSActive portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment is focused in areas that offer best opportunities for success PORTFOLIO TRAN
Slide 27: Barclays Global Healthcare Conference
03 | 09 | 2021 ANGIODYNAMICS Barclays Global Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 28
Slide 28: Barclays Global Healthcare Conference
ANGIODYNAMICS Barclays Global Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO i>) angiodynamics
Slide 29: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees
Slide 30: Reconciliation of GAAP to Non-GAAP
@ @ @ Reconciliation of GAAP to Non-GAAP Net Income and EPS Six months ended for 30,2019, (audited) Net oss s 639) 8 ony Amortization of intangibles 9.846 8.398 ‘Change in fir value of contingent consideration a7) (G03) Acquisition, restroctoring and other items, net) 2447 2901 Write-off of deferred
Slide 31: AngioVac Cannula Indication for Use
AngioVac Cannula Indication for Use: The AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours. | Contraindications: Contraindicated for patients with severe arterial or venous vascular disea
AngioDynamics — Barclays Global Healthcare Conference 2021 on 6ix